JTI Healthcare Portfolio

Jubile Tech Incubator (JTI) was a London-based incubator I co-founded in 2021. Under the JTI umbrella, we shipped two healthcare ventures targeting the US market — both focused on removing friction from patient access to specialist care. I was Co-founder of the shareholding company, Lead Engineer on both products, and Tech Advisor through their growth phases. Both products are still operating as of 2026 — my direct tenure ended February 2025. **AskMindi — telehealth with a curated treatment angle** (Aug 2022 – Feb 2025, ~30 months) AskMindi let patients book verified providers for telehealth consultations from their phone — but with a unique angle: each consultation surfaced both conventional pharmaceutical options and peer-reviewed natural/supplement protocols, letting patients choose between treatment philosophies while staying inside the regulated medical system. Prescriptions routed directly to local pharmacies; free membership, low-friction onboarding. **WoundLocal — mobile wound care in Texas** (Early 2024 – Feb 2025, ~12 months) WoundLocal brought specialist wound care to the patient's home or care facility, eliminating the 3-7 day in-clinic visit cycle that's the dominant cause of treatment abandonment for chronic wounds. Insurance handled billing — patients paid nothing. The operational challenge wasn't just scheduling — it was matching specialist skills to wound types, optimizing multi-stop routes across Texas geography, and handling the complex US payor mix without burying the clinic in administrative overhead.

Both products required HIPAA-compliant architecture from day one — no retrofitting.

The hardest UX problem in healthcare is building software that clinicians will actually use between patients. The second-hardest is navigating US healthcare operational complexity: payor relationships, prescription regulations, mobile care logistics, multi-state provider licensing.

Both AskMindi and WoundLocal had to solve these problems while serving real patients — not as prototypes, but as production systems where a bug could affect someone's care.

Both AskMindi and WoundLocal launched into US markets and reached operational scale during my tenure (Aug 2022 – Feb 2025). The most important outcome is the simplest: **both products are still operating today**, serving real patients, growing post my engineering leadership transition.

**What this work demonstrates:** • How to architect HIPAA-compliant systems from day one (not retrofitted) • How to ship healthcare software that survives clinician workflows • How to operate as both founder (equity, strategic decisions) and engineer (hands-on shipping) • US healthcare-specific operational complexity at production scale

These builds inform the AI work I do today: production systems where regulatory compliance, clinician workflow accommodation, and operational reliability are non-negotiable. AI tools for healthcare, regulated industries, or any context where "move fast and break things" is unacceptable — that's exactly the discipline I built across AskMindi and WoundLocal.